Company intelligence / Profile preview

STENTiT

Eindhoven, North Brabant, Netherlands

Ownership: Private
Employees: ~10
Development stage: Other

Overview

STENTiT has successfully initiated first-in-human clinical trials (VITAL-IT 1) implanting its Resorbable Fibrillated Scaffold (RFS) in patients with below-the-knee chronic limb-threatening ischemia (CLTI). The RFS is fully bioresorbable, provides temporary support, and triggers natural artery regeneration. Early clinical results demonstrate restoration of blood flow with minimally invasive procedures; long-term patient monitoring is underway to assess durability and safety.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Eindhoven University of Technology (TU/e)Medical University of GrazEuropean Innovation Council

Beyond the preview

Go deeper on STENTiT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STENTiT.

Explore the full profile